Loading clinical trials...
Loading clinical trials...
Pre- Versus Postoperative Accelerated Partial Breast Irradiation in Early Stage Breast Cancer Patients
Most of the local recurrences (LR) found after breast-conserving therapy are within or close to the tumor bed. This pattern of recurrence was confirmed by studies of breast conserving surgery without adjuvant irradiation and by the update of the NSABP B-06 trial. In the EORTC boost trial, however, 29% of all LR were found outside the area of the original tumor. Still, a recent review of Breast Conserving Therapy (BCT) trials showed that the site of local recurrences after BCT was mostly in the tumor bed, with less than 10% of LR elsewhere in the breast. This led to the concept of partial breast irradiation. With accelerated partial breast irradiation (APBI), a limited volume of breast tissue is irradiated, allowing for a higher dose per fraction compared to whole breast irradiation (WBI), which is favorable considering the low alpha/beta ratio, and thus higher sensitivity to high dose per fraction.
Patients will undergo a partial accelerated breast irradiation pre-or postoperative of 5 x 5.2 Gy
Age
51 - No limit years
Sex
FEMALE
Healthy Volunteers
No
Institut Curie
Saint-Cloud, France
Institut Gustave-Roussy
Villejuif, France
Antoni van Leeuwenhoek
Amsterdam, Netherlands
University Medical Center Utrecht (UMCU)
Utrecht, Netherlands
Champilamaud Cancer Center
Lisbon, Portugal
University General Hospital Valencia-Erasa
Valencia, Spain
Start Date
November 10, 2016
Primary Completion Date
February 28, 2022
Completion Date
February 28, 2022
Last Updated
September 29, 2022
65
ACTUAL participants
partial breast irradiation
RADIATION
Lead Sponsor
The Netherlands Cancer Institute
Collaborators
NCT05673200
NCT05245812
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions